Skandinaviska Enskilda Banken Ab (Publ) Mannkind Corp Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

  • $21.5 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$3.34 - $4.29 $290,914 - $373,659
87,100 New
87,100 $317,000
Q1 2021

May 14, 2021
SELL
$3.14 - $6.14 $570,224 - $1.12 Million
-181,600 Closed
0 $0
Q3 2020

Nov 12, 2020
SELL
$1.56 - $2.08 $225,264 - $300,352
-144,400 Reduced 44.29%
181,600 $341,000
Q2 2020

Aug 13, 2020
BUY
$0.94 - $2.21 $306,440 - $720,460
326,000 New
326,000 $571,000

Others Institutions Holding MNKD

# of Institutions
245
Shares Held
148M
Call Options Held
1.62M
Put Options Held
802K
View Full List

About MANNKIND CORP

MNKD Quotes by TradingView
  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.81B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email